✓ 100 µl (10 western blots)



**Orders** 877-616-CELL (2355)

orders@cellsignal.com

**Support** 877-678-TECH (8324)

info@cellsignal.com

Web www.cellsignal.com

New 11/12

## For Research Use Only. Not For Use In Diagnostic Procedures.

Applications	Species Cross-Reactivity*	Molecular Wt.	Source	
W, IP	Н	43 kDa	Rabbit**	
Endoaenous				


Background: INDO/IDO1/indoleamine 2,3-dioxygenase (IDO) is an IFN-y-inducible enzyme that catalyzes the ratelimiting step of tryptophan degradation (1). IDO is upregulated in many tumors and in dendritic cells in tumor-draining lymph nodes. Elevated tryptophan catabolism in these cells leads to tryptophan starvation of T cells, limiting T cell proliferation and activation (2). Therefore, IDO is considered an immunosuppresive molecule, and research studies have shown that upregulation of IDO is a mechanism of cancer immune evasion (3). The gastrointestinal stromal tumor drug, imatinib, was found to act, in part, by reducing IDO expression, resulting in increased CD8+ T cell activation and induction of apoptosis in regulatory T cells (4). In addition to its enzymatic activity, IDO was recently shown to have signaling capability through an immunoreceptor tyrosinebased inhibitory motif (ITIM) that is phosphorylated by Fvn in response to TGF-β. This leads to recruitment of SHP-1 and activatation of the noncanonical NF-κB pathway (5).

**Specificity/Sensitivity:** IDO Antibody recognizes endogenous levels of total IDO protein.


**Source/Purification:** Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human IDO protein. Antibodies are purified by protein A and peptide affinity chromatography.

## **Background References:**

- (1) Yasui, H. et al. (1986) *Proc. Natl. Acad. Sci. USA* 83, 6622–6626
- (2) Mellor, A.L. et al. (2003) *Adv. Exp. Med. Biol.* 527, 27-35
- (3) Prendergast, G.C. (2008) Oncogene 27, 3889–3900.
- (4) Balachandran, V.P. et al. (2011) *Nat. Med.* 17, 1094–1100.
- (5) Pallotta, M.T. et al. (2011) Nat. Immunol. 12, 870-878.



Western blot analysis of extracts from HeLa cells, untreated (-) or treated; + with Human Interferon- $\gamma$  (hIFN- $\gamma$ ) #8901 (10 ng/ml, 16 hr; +), using IDO Antibody (upper) or  $\beta$ -Actin (D6A8) Rabbit mAb #8457 (lower).



Western blot analysis of extracts from 293T cells, mock transfected (-) or transfected with a construct expressing full-length human IDO (hIDO; +), using IDO Antibody.

Entrez-Gene ID #3620 Swiss-Prot Acc. #P14902

**Storage:** Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100  $\mu$ g/ml BSA and 50% glycerol. Store at  $-20^{\circ}$ C. Do not aliquot the antibody.

\*Species cross-reactivity is determined by western blot.


\*\*Anti-rabbit secondary antibodies must be used to detect this antibody.

## **Recommended Antibody Dilutions:**

Western blotting 1:1000 Immunoprecipitation 1:50

For product specific protocols please see the web page for this product at www.cellsignal.com.

Please visit www.cellsignal.com for a complete listing of recommended complementary products.



Immunoprecipitation of IDO from HeLa cells, treated with Human Interferon-\(\gamma\) (HIFN-\(\gamma\)) #8901 (10 ng/ml, 16 hr), using Normal Rabbit IgG #2729 (Iane 2) or IDO Antibody (Iane 3). Lane 1 is 10% input. Western blot analysis was performed using IDO Antibody.

IMPORTANT: For western blots, incubate membrane with diluted antibody in 5% w/v BSA, 1X TBS, 0.1% Tween-20 at 4°C with gentle shaking, overnight.

© 2012 Cell Signaling Technology, Inc. Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.